General and Administrative Expense of AYTU BIOPHARMA, INC from 30 Nov 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Summary
AYTU BIOPHARMA, INC quarterly and annual General and Administrative Expense in USD history and change rate from 30 Nov 2010 to 31 Dec 2025.
  • AYTU BIOPHARMA, INC General and Administrative Expense for the quarter ending 31 Dec 2025 was $5,070,000, a 14% increase year-over-year.
  • AYTU BIOPHARMA, INC General and Administrative Expense for the twelve months ending 31 Dec 2025 was $17,799,000, a 3.4% decline year-over-year.
  • AYTU BIOPHARMA, INC annual General and Administrative Expense for 2025 was $17,379,000, a 13% decline from 2024.
  • AYTU BIOPHARMA, INC annual General and Administrative Expense for 2024 was $19,954,000, a 30% decline from 2023.
  • AYTU BIOPHARMA, INC annual General and Administrative Expense for 2023 was $28,630,000, a 8.1% decline from 2022.
Source SEC data
View on sec.gov
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Quarterly (USD)
General and Administrative Expense, YoY Quarterly Change (%)
General and Administrative Expense, Annual (USD)
General and Administrative Expense, YoY Annual Change (%)

AYTU BIOPHARMA, INC Quarterly General and Administrative Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $17,799,000 $5,070,000 +$621,000 +14% 01 Oct 2025 31 Dec 2025 10-Q 03 Feb 2026 2026 Q2
Q3 2025 $17,178,000 $4,924,000 -$201,000 -3.9% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2026 Q1
Q2 2025 $17,379,000 $3,696,000 -$332,000 -8.2% 01 Apr 2025 30 Jun 2025 10-K 23 Sep 2025 2025 FY
Q1 2025 $17,711,000 $4,109,000 -$722,000 -15% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q3
Q4 2024 $18,433,000 $4,449,000 -$351,000 -7.3% 01 Oct 2024 31 Dec 2024 10-Q 03 Feb 2026 2026 Q2
Q3 2024 $18,784,000 $5,125,000 -$1,170,000 -19% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2026 Q1
Q2 2024 $19,954,000 $4,028,000 -$2,085,000 -34% 01 Apr 2024 30 Jun 2024 10-K 23 Sep 2025 2025 FY
Q1 2024 $22,039,000 $4,831,000 -$2,346,000 -33% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q3
Q4 2023 $24,385,000 $4,800,000 -$3,218,000 -40% 01 Oct 2023 31 Dec 2023 10-Q 12 Feb 2025 2025 Q2
Q3 2023 $27,603,000 $6,295,000 -$1,027,000 -14% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2025 Q1
Q2 2023 $28,630,000 $6,113,000 -$1,269,000 -17% 01 Apr 2023 30 Jun 2023 10-K 26 Sep 2024 2024 FY
Q1 2023 $29,899,000 $7,177,000 -$439,000 -5.8% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q3
Q4 2022 $30,338,000 $8,018,000 +$65,000 +0.82% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024 2024 Q2
Q3 2022 $30,273,000 $7,322,000 -$894,000 -11% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2024 Q1
Q2 2022 $31,167,000 $7,382,000 -$1,113,000 -13% 01 Apr 2022 30 Jun 2022 10-K 12 Oct 2023 2023 FY
Q1 2022 $32,280,000 $7,616,000 +$1,615,000 +27% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q3
Q4 2021 $30,665,000 $7,953,000 +$2,369,000 +42% 01 Oct 2021 31 Dec 2021 10-Q 21 Feb 2023 2023 Q2
Q3 2021 $28,296,000 $8,216,000 +$2,796,000 +52% 01 Jul 2021 30 Sep 2021 10-Q/A 21 Feb 2023 2023 Q1
Q2 2021 $25,500,000 $8,495,000 01 Apr 2021 30 Jun 2021 10-K 27 Sep 2022 2022 FY
Q1 2021 $6,001,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q3
Q4 2020 $5,584,000 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022 2022 Q2
Q3 2020 $5,420,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2022 Q1
Q1 2015 $1,087,788 +$350,761 +48% 01 Jan 2015 31 Mar 2015 10-Q 19 May 2015 2015 Q3
Q4 2014 $5,274,000 +$5,267,379 01 Sep 2014 30 Nov 2014 10-Q 12 Jan 2015 2015 Q1
Q2 2014 $5,865,348 $5,116,000 +$5,106,672 +54746% 01 Mar 2014 31 May 2014 10-Q 10 Jul 2014 2014 Q3
Q1 2014 $758,676 $737,027 +$728,928 01 Jan 2014 31 Mar 2014 10-Q 19 May 2015 2015 Q3
Q4 2013 $29,748 $6,621* -$156 01 Sep 2013 30 Nov 2013 10-Q 12 Jan 2015 2015 Q1
Q3 2013 $29,904 $5,700 +$4,412,741 01 Jun 2013 31 Aug 2013 10-K 26 Nov 2014 2013 FY
Q2 2013 $4,382,837 $9,328 +$3,499 01 Mar 2013 31 May 2013 10-Q 10 Jul 2014 2014 Q3
Q1 2013 $4,386,336 $8,099* -$4,417,901 01 Dec 2012 28 Feb 2013 10-Q 11 Apr 2014 2014 Q2
Q4 2012 $31,565 $6,777* -$2,015 01 Sep 2012 30 Nov 2012 10-Q 10 Jan 2014 2014 Q1
Q3 2012 $33,580 $4,407,041 -$4,451,175 -10086% 01 Jun 2012 31 Aug 2012 10-K 26 Nov 2014 2013 FY
Q2 2012 $4,484,755 $5,829* -$8,406 01 Mar 2012 31 May 2012 10-Q 26 Jun 2012 2012 Q3
Q1 2012 $4,493,161 $4,426,000 +$4,407,787 +24201% 01 Dec 2011 29 Feb 2012 10-Q 12 Apr 2012 2012 Q2
Q4 2011 $85,374 $8,792* +$692 01 Sep 2011 30 Nov 2011 10-Q 14 Jan 2013 2013 Q1
Q3 2011 $84,682 $44,134 01 Jun 2011 31 Aug 2011 10-K 29 Nov 2012 2012 FY
Q2 2011 $14,235 01 Mar 2011 31 May 2011 10-Q 26 Jun 2012 2012 Q3
Q1 2011 $18,213 01 Dec 2010 28 Feb 2011 10-Q 12 Apr 2012 2012 Q2
Q4 2010 $8,100* 01 Sep 2010 30 Nov 2010 10-Q 23 Dec 2011 2012 Q1

AYTU BIOPHARMA, INC Annual General and Administrative Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $17,379,000 -$2,575,000 -13% 01 Jul 2024 30 Jun 2025 10-K 23 Sep 2025 2025 FY
2024 $19,954,000 -$8,676,000 -30% 01 Jul 2023 30 Jun 2024 10-K 23 Sep 2025 2025 FY
2023 $28,630,000 -$2,537,000 -8.1% 01 Jul 2022 30 Jun 2023 10-K 26 Sep 2024 2024 FY
2022 $31,167,000 +$5,667,000 +22% 01 Jul 2021 30 Jun 2022 10-K 12 Oct 2023 2023 FY
2021 $25,500,000 +$5,843,000 +30% 01 Jul 2020 30 Jun 2021 10-K 27 Sep 2022 2022 FY
2020 $19,657,000 01 Jul 2019 30 Jun 2020 10-K 28 Sep 2021 2021 FY
2015 $4,382,640 +$2,036,083 +87% 01 Jul 2014 30 Jun 2015 10-K 28 Sep 2015 2015 FY
2014 $2,346,557 +$2,316,653 +7747% 01 Jul 2013 30 Jun 2014 10-K 28 Sep 2015 2015 FY
2013 $29,904 -$3,676 -11% 01 Sep 2012 31 Aug 2013 10-K 26 Nov 2014 2013 FY
2012 $33,580 -$51,102 -60% 01 Sep 2011 31 Aug 2012 10-K 26 Nov 2014 2013 FY
2011 $84,682 01 Sep 2010 31 Aug 2011 10-K 29 Nov 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.